Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
Period EndTotal current liabilities (Million JPY)YoY (%)
Mar 31, 20254,319+81.83%
Mar 31, 20242,375+124.96%
Mar 31, 20231,056-6.44%
Mar 31, 20221,129+1.28%
Mar 31, 20211,114+26.49%
Mar 31, 2020881+120.16%
Mar 31, 2019400-1.19%
Mar 31, 2018405+113.88%
Mar 31, 2017189-85.20%
Mar 31, 20161,280+1287.80%
Mar 31, 201592
AI Chat